CytoReason vs Ukko
CytoReason vs Ukko, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Ukko on 62/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 62/100
- domain rating: 40/100 against 20/100
- headcount: 116 against 58
- headcount growth: +13.7% against -0.5%
- funding raised: $128M against $40.0M
- LinkedIn following: 12,830 against 5,436
Ukko
- agent readiness: 51/100 against 21/100
At a glance
| Measure | CytoReason | Ukko |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Ukko is developing novel food allergy and disorder treatments using advanced immunology and plant science. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Allergen, Immunology, Celiac |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2016 | 2016 |
| Headquarters | Tel Aviv, Israel | Palo Alto, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | CytoReason | Ukko |
|---|---|---|
| Employees | 116 | 58 |
| Headcount growthLast 12 months | +13.7% | -0.5% |
| Total funding | $128M | $40.0M |
| Latest round | Series B | Series B |
| LinkedIn followers | 12,830 | 5,436 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Ukko |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 62/100 |
| Traction | 60/100 | 56/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 30/100 | 30/100 |
| Quality | 78/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | D (51/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 20/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Ukko |
|---|---|---|
| CMS | Not detected | Wix |
| Analytics | Segment | Not detected |
CytoReason vs Ukko: common questions
Which is better, CytoReason or Ukko?
On our 0-100 score CytoReason rates higher (68/100 against 62/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do CytoReason and Ukko compare on the numbers?
CytoReason leads on our overall score (68/100 against 62/100), domain rating (40/100 against 20/100), headcount (116 against 58), headcount growth (+13.7% against -0.5%), funding raised ($128M against $40.0M), LinkedIn following (12,830 against 5,436). Ukko leads on agent readiness (51/100 against 21/100).
Read the full CytoReason review and pricing or the Ukko review and pricing. You can also browse other CytoReason alternatives we track.